Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fractyl Health (GUTS) EBITDA (2023 - 2025)

Fractyl Health's EBITDA history spans 3 years, with the latest figure at -$23.3 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 7.64% year-over-year to -$23.3 million, compared with a TTM value of -$96.8 million through Dec 2025, down 3.51%, and an annual FY2025 reading of -$96.8 million, down 3.51% over the prior year.
  • EBITDA for Q4 2025 was -$23.3 million at Fractyl Health, down from -$22.7 million in the prior quarter.
  • The five-year high for EBITDA was -$11.9 million in Q2 2023, with the low at -$26.1 million in Q2 2025.
  • Average EBITDA over 3 years is -$20.1 million, with a median of -$22.8 million recorded in 2024.
  • Year-over-year, EBITDA crashed 94.21% in 2024 and then grew 7.64% in 2025.
  • Tracing GUTS's EBITDA over 3 years: stood at -$13.0 million in 2023, then plummeted by 94.21% to -$25.2 million in 2024, then grew by 7.64% to -$23.3 million in 2025.
  • Per Business Quant, the three most recent readings for GUTS's EBITDA are -$23.3 million (Q4 2025), -$22.7 million (Q3 2025), and -$26.1 million (Q2 2025).